Search the Newsreel

Pfizer and Valneva’s Lyme Disease Vaccine Candidate Marketing Authorization Application Validated by European Medicines Agency

Submission based on favorable efficacy and safety results from Phase 3 VALOR trial NEW YORK & LYON, France, August 14, 2026--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced that the European Medicines Agency (EMA) has validated the …

How Pfizer’s Higher 2026 Guidance And LITFULO Trial Results At Pfizer (PFE) Have Changed Its Investment Story

In early August 2026, Pfizer Inc. reported second-quarter results showing revenue of US$15,034 million and a net loss of US$248 million, alongside US$4.30 billion in non-cash intangible asset impairments and a modest increase in full-year 2026 revenue guidance to US$60.50–US$62.50 billion. A key offsetting …

Pfizer CEO Buys $1 Million of Stock

This article first appeared on GuruFocus. Pfizer Inc. (PFE, Financials) The pharmaceutical giant earned a new vote of confidence from its top executive. Albert Bourla bought about $1 million worth of company stock. Bourla purchased 38,000 shares at $26.34 apiece, which increased his ownership …

5 Insightful Analyst Questions From Pfizer’s Q2 Earnings Call

5 Insightful Analyst Questions From Pfizer's Q2 Earnings Call Pfizer's second quarter results reflected stability in its core business despite ongoing challenges in COVID-related product demand. The company's performance was shaped by strong execution in its non-COVID portfolio, with management highlighting robust revenue contributions …

Will Pfizer's Non-COVID Portfolio Drive Its Next Phase of Growth?

Pfizer's PFE business mix has changed significantly over the past few years. During the pandemic, the company became heavily dependent on COVID-19 products, Comirnaty (COVID-19 vaccine) and Paxlovid (oral antiviral). However, the company is gradually diversifying its portfolio through a combination of internal product …

Projeções de Resultados: Pfizer Inc (PFE) — LPA e Crescimento de Receita

Pfizer (PFE) Agreed To A $44 Million Chantix Settlement

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Pfizer (NYSE:PFE) agreed to a US$44 million class action settlement related to its smoking cessation drug Chantix, addressing claims tied to product safety disclosures. …

Pfizer (PFE) Q2 2026 Earnings Call Transcript

Image source: The Motley Fool. DATE Tuesday, Aug. 4, 2026 at 11:00 a.m. ET CALL PARTICIPANTS Chairman and Chief Executive Officer - Albert Bourla Chief Financial Officer - David Denton Incoming Interim Chief Financial Officer and Executive Vice President - Cecile Guegan Chief Scientific …

Pfizer Inc. (PFE) vs. BioNTech SE (BNTX): Which Pharma Giant Is Better Positioned for the Post-COVID Era?

Pfizer Inc. (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX), two companies forever linked by their historic COVID-19 vaccine partnership, reported Q2 2026 earnings alongside major strategic announcements. While the European Commission authorized their updated XFG-adapted COVID-19 vaccine on July 29, the two partners are traveling down …

Pfizer Rises Almost 7% Post Q2 Results: How to Play the Stock

Pfizer PFE stock has risen 6.9% since it announced second-quarter 2026 results on Aug. 4. Pfizer delivered a solid second quarter, beating estimates for both earnings and revenues. While earnings growth was flat year over year, revenues rose 1% on an operational basis. Strength …

Insider trades: Microsoft, Meta, Pfizer among notable names

[Meta European head office] Derick Hudson Insider transactions were seen across major firms this week, including Microsoft (MSFT [https://seekingalpha.com/symbol/MSFT]) and Meta (META [https://seekingalpha.com/symbol/META]). The following trades took place between August 3 and August 7. * Microsoft (MSFT [https://seekingalpha.com/symbol/MSFT]) saw two executives divest a small …

Análise e Previsão das Ações da Pfizer Inc (PFE)

Pfizer's Next Weight-Loss Weapon: How Berobenatide Stacks Up Against Novo Nordisk's Wegovy and Eli Lilly's Zepbound

Key Points Pfizer's berobenatide appears to be a promising candidate that could challenge Wegovy and Zepbound. There are several other reasons to consider the stock, despite the potential headwinds ahead. 10 stocks we like better than Pfizer › The past few years have been …

Global Influenza Vaccine Market Report, 2026 Edition - Profiles GlaxoSmithKline, Pfizer, Sanofi, Moderna, and 9 Other Players

Company Logo Dublin, Aug. 07, 2026 (GLOBE NEWSWIRE) -- The "Global Influenza Vaccine Market: 2026 Edition" has been added to ResearchAndMarkets.com's offering. The global influenza vaccine market was valued at US$8.96 billion in 2024 and is projected to reach US$13.32 billion by 2030, expanding …

Novavax Inc (NVAX) (Q2 2026) Earnings Call Highlights: Matrix-M Momentum Drives Revenue ...

This article first appeared on GuruFocus. Release Date: August 06, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Novavax Inc (NASDAQ:NVAX) has secured licensing or material transfer agreements with 4 of the TOP10 …

Pfizer (PFE) Could Be 12% Undervalued Following Raised 2026 Revenue Guidance

Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Pfizer (PFE) is back in focus after its second quarter 2026 update, which paired a reported net loss and sizeable non cash impairments with higher full year …

Pfizer Stock Slips Despite Earnings Beat and $2.5 Billion Cuts

This article first appeared on GuruFocus. Pfizer (NYSE:PFE), the pharmaceutical giant behind some of the world's biggest blockbuster drugs, edged about 0.5% lower in Tuesday's early trading despite delivering another earnings beat and raising its revenue outlook. The market appeared unconvinced that better quarterly …

Pfizer Q2 Earnings Call Highlights Non-COVID Growth and Cost Cuts

Pfizer Inc. PFE used its second-quarter 2026 earnings call to stress that stronger non-COVID products are offsetting a weak infection season as investment targets oncology and obesity. Management raised the midpoint of full-year revenue guidance, expanded savings targets and reinforced the dividend. The call …

Company News for Aug 5, 2026

Allison Transmission Holdings Inc.'s (ALSN) shares surged 5.4% after reporting second-quarter 2026 adjusted earnings of $2.73 per share, surpassing the Zacks Consensus Estimate of $2.60 per share. Shares of The Clorox Co. (CLX) climbed 6.5% after posting fourth-quarter fiscal 2026 adjusted earnings of $1.66 …

Pfizer Earnings Reveal New Engine Beyond Covid

This article first appeared on GuruFocus. Pfizer (NYSE:PFE) delivered stronger-than-expected second-quarter results as Specialty Care and newer acquired medicines offset continued weakness across Primary Care, reinforcing the company's transition away from pandemic-era products. The split matters because Pfizer's recovery increasingly depends on specialty drugs …

PFE Q2 Earnings Top, 2026 Sales View Tweaked, COVID Forecast Cut

Pfizer PFEreported second-quarter 2026 adjusted earnings per share of 77 cents, which beat the Zacks Consensus Estimate of 68 cents per share. Earnings were flat year over year. Revenues came in at $15.03 billion, up 3% from the year-ago quarter on a reported basis …

Pfizer's Recovery Story Is Starting to Look More Durable

This article first appeared on GuruFocus. Pfizer Inc. (PFE, Financials), the pharmaceutical firm, said its second-quarter earnings topped Wall Street estimates and boosted its annual revenue guidance, as growth in its non-COVID portfolio compensated for a steep drop in Paxlovid sales.Adjusted earnings of 77 …

Pfizer Ducks Continued Covid Fallout As Hard-Fought Obesity Readout Looms

Pfizer beat second-quarter expectations Tuesday, offsetting a continued steep decline for its Covid products. But Pfizer stock fell. Continue Reading

Compared to Estimates, Pfizer (PFE) Q2 Earnings: A Look at Key Metrics

Pfizer (PFE) reported $15.03 billion in revenue for the quarter ended June 2026, representing a year-over-year increase of 2.6%. EPS of $0.77 for the same period compares to $0.78 a year ago. The reported revenue compares to the Zacks Consensus Estimate of $14.45 billion, …

NYSE Content Update: ADI to Make NYSE Trading Debut After Spin-Off

NYSE issues a pre-market daily advisory direct from the trading floor. NEW YORK, Aug. 4, 2026 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before …

Pfizer’s (NYSE:PFE) Q2 CY2026: Beats On Revenue

Pfizer's (NYSE:PFE) Q2 CY2026: Beats On Revenue Global pharmaceutical company Pfizer (NYSE:PFE) reported Q2 CY2026 results beating Wall Street's revenue expectations , with sales up 2.6% year on year to $15.03 billion. The company expects the full year's revenue to be around $61.5 billion, …

Pfizer (PFE) Reports Positive Phase 3 LITFULO Data In Vitiligo

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Pfizer (NYSE:PFE) reported positive Phase 3 results for LITFULO in nonsegmental vitiligo. The company plans to pursue global regulatory filings for LITFULO as …

Why Pfizer Stock and This Covid Vaccine Partner Are Falling on Earnings

Pfizer beats earnings forecasts for the second quarter, while BioNTech’s results miss expectations due to weak Covid vaccine demand. Continue Reading

Pfizer Reports Second-Quarter Results And Raises Midpoint of 2026 Revenue Guidance

Focused Execution Drove 18% Operational Revenue Growth of Launched and Acquired Products(1) Advancing Robust Late-Stage Pipeline, with Several Key Pivotal Readouts Expected Over Next 12 Months Announces Expansion of Productivity Enhancement Initiatives NEW YORK, August 04, 2026--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) reported financial results …

Pfizer (PFE) Q2 Earnings: What To Expect

Pfizer (PFE) Q2 Earnings: What To Expect Global pharmaceutical company Pfizer (NYSE:PFE) will be reporting earnings this Tuesday before market hours. Here's what to expect. Pfizer beat analysts' revenue expectations last quarter, reporting revenues of $14.45 billion, up 5.4% year on year. It was …

Pfizer (PFE) Stock Looks Reasonable Based On Today’s Broader Checks

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Pfizer stock has declined 27.7% over the past 5 years, yet the current valuation checks and market multiples now point to a picture that looks …

Here is What to Know Beyond Why Pfizer Inc. (PFE) is a Trending Stock

Pfizer (PFE) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future. Over the past month, shares of this drugmaker have returned …

Pfizer Announces Positive Topline Phase 3 Results for LITFULO in Patients with Nonsegmental Vitiligo

Two pivotal studies of LITFULO™ (ritlecitinib) in nonsegmental vitiligo met their co-primary endpoints, showing significant improvement in facial and total repigmentation versus placebo at Week 52 LITFULO was studied in the largest Phase 3 program to date evaluating an oral systemic therapy for nonsegmental …